Smith Kristin N, Kopacz Dan J, McDonald Susan B
From the Department of Anesthesiology, Virginia Mason Medical Center, Seattle, Washington.
Anesth Analg. 2004 Jan;98(1):81-88. doi: 10.1213/01.ANE.0000093361.48458.6E.
With the availability of preservative- and antioxidant-free 2-chloroprocaine (2-CP), there may be an acceptable short-acting alternative to lidocaine for spinal anesthesia. We examined the safety, dose-response characteristics, and effects of epinephrine with spinal 2-CP. Six volunteers per group were randomized to receive 30, 45, or 60 mg of spinal 2-CP with and without epinephrine. Intensity and duration of sensory and motor blockade were assessed. When 11 of the 18 volunteers complained of vague, nonspecific flu-like symptoms, breaking of the blind revealed that all spinal anesthetics associated with the flu-like symptoms contained epinephrine. There were no complaints of flu-like symptoms in the volunteers who received 2-CP without epinephrine. No further spinal anesthetics containing epinephrine were administered, resulting in 29 anesthetics (11 with epinephrine, 18 without epinephrine.) Plain 2-CP demonstrated a dose-dependent increase in peak block height and duration of effect at all variables except time to 2-segment regression and time to regression to T10. Time to complete sensory regression with plain 2-CP was 98 +/- 20, 116 +/- 15, and 132 +/- 23 min, respectively. 2-CP with epinephrine produced times to complete sensory regression of 153 +/- 25, 162 +/- 33, and 148 +/- 29 min, respectively. Preservative and antioxidant free 2-CP can be used effectively for spinal anesthesia in doses of 30-60 mg. Epinephrine is not recommended as an adjunct because of the frequent incidence of side effects.
Hyperbaric spinal 2-chloroprocaine is effective and has an anesthetic profile appropriate for use in the surgical outpatient over the dose range of 30-60 mg without signs of transient neurologic symptoms. The addition of epinephrine is not recommended because of the frequent incidence of side effects.
随着不含防腐剂和抗氧化剂的2-氯普鲁卡因(2-CP)的出现,它可能成为一种可接受的用于脊髓麻醉的短效利多卡因替代药物。我们研究了脊髓注射2-CP时的安全性、剂量反应特征以及肾上腺素的作用。每组6名志愿者被随机分配接受30、45或60毫克含或不含肾上腺素的脊髓2-CP。评估感觉和运动阻滞的强度及持续时间。18名志愿者中有11人抱怨有模糊的、非特异性的流感样症状,盲法被打破后发现,所有与流感样症状相关的脊髓麻醉剂都含有肾上腺素。接受不含肾上腺素的2-CP的志愿者没有出现流感样症状的抱怨。不再给予含肾上腺素的脊髓麻醉剂,最终共有29次麻醉(11次含肾上腺素,18次不含肾上腺素)。普通2-CP在除2节段恢复时间和恢复到T10时间外的所有变量上均表现出剂量依赖性的峰值阻滞高度增加和作用持续时间延长。普通2-CP完成感觉恢复的时间分别为98±20、116±15和132±23分钟。含肾上腺素的2-CP完成感觉恢复的时间分别为153±25、162±33和148±29分钟。不含防腐剂和抗氧化剂的2-CP在30 - 60毫克剂量下可有效用于脊髓麻醉。由于副作用发生率高,不建议将肾上腺素作为辅助药物。
高压脊髓2-氯普鲁卡因是有效的,在30 - 60毫克剂量范围内具有适合外科门诊使用的麻醉特征,且无短暂性神经症状迹象。由于副作用发生率高,不建议添加肾上腺素。